Presentation is loading. Please wait.

Presentation is loading. Please wait.

REAL-WORLD SAFETY, EFFECTIVENESS, AND PATIENT-REPORTED OUTCOMES IN PATIENTS WITH CHRONIC HEPATITIS C VIRUS INFECTION TREATED WITH GLECAPREVIR/PIBRENTASVIR:

Published byWidyawati Wibowo Modified over 5 years ago

Similar presentations

Presentation on theme: "REAL-WORLD SAFETY, EFFECTIVENESS, AND PATIENT-REPORTED OUTCOMES IN PATIENTS WITH CHRONIC HEPATITIS C VIRUS INFECTION TREATED WITH GLECAPREVIR/PIBRENTASVIR:"— Presentation transcript:

1 REAL-WORLD SAFETY, EFFECTIVENESS, AND PATIENT-REPORTED OUTCOMES IN PATIENTS WITH CHRONIC HEPATITIS C VIRUS INFECTION TREATED WITH GLECAPREVIR/PIBRENTASVIR: DATA FROM THE GERMAN HEPATITIS C-REGISTRY

2 Disclosures

3 Disclosures

4 German Hepatitis C-Registry (DHC‐R)

5 Background and Objective

6 Study Population Receiving On-Label Glecaprevir/Pibrentasvir

7 Demographics and Clinical Characteristics at Baseline

8 Demographics and Clinical Characteristics at Baseline

9 SVR12 Rates in the Effectiveness Population

10 SVR12 Rates in the Effectiveness Population

11 SVR12 Rates in HCV Treatment-Naïve Non-Cirrhotic Patients

12 SF-36 Component Summary Scores at Baseline

13 SF-36 Physical Component Summary Score

14 SF-36 Mental Component Summary Score

15 Safety

16 Summary

Download ppt "REAL-WORLD SAFETY, EFFECTIVENESS, AND PATIENT-REPORTED OUTCOMES IN PATIENTS WITH CHRONIC HEPATITIS C VIRUS INFECTION TREATED WITH GLECAPREVIR/PIBRENTASVIR:"

Similar presentations

Hepatitis web study Hepatitis web study Sofosbuvir + Ribavirin in HCV GT 4 Egyptian Ancestry Trial Phase 2 Ruane PJ, et al. J Hepatol. 2015;62:1040-6.

Hepatitis web study Hepatitis web study Sofosbuvir + Ribavirin in HCV GT 4 Egyptian Ancestry Trial Phase 2 Ruane PJ, et al. J Hepatol. 2015;62:
Kwo PY. NEJM 2014;371:2375-82 CORAL-I  Design OBV/PTV/r + DSV + RBV Open label Phase II 18-70 years Chronic HCV infection, genotype 1 Liver transplantation.

Kwo PY. NEJM 2014;371: CORAL-I  Design OBV/PTV/r + DSV + RBV Open label Phase II years Chronic HCV infection, genotype 1 Liver transplantation.
NIAID ERADICATE Open-label W12 ≥ 18 years Chronic HCV infection Genotype 1 Treatment naïve HIV infection on stable ART ≥ 8 weeks and HIV RNA < 50 c/ml.

NIAID ERADICATE Open-label W12 ≥ 18 years Chronic HCV infection Genotype 1 Treatment naïve HIV infection on stable ART ≥ 8 weeks and HIV RNA < 50 c/ml.
Hepatitis web study Hepatitis web study Sofosbuvir + Ribavirin in HCV Genotype 1 NIAID/NIH Trial Phase 2, Treatment Naïve Treatment Naïve (unfavorable.

Hepatitis web study Hepatitis web study Sofosbuvir + Ribavirin in HCV Genotype 1 NIAID/NIH Trial Phase 2, Treatment Naïve Treatment Naïve (unfavorable.
Supplemental Figure Legends Supplemental Figure 1a: SF-36. SF-36 mental component score among subjects randomized to SAMe or placebo, at baseline, Week.

Supplemental Figure Legends Supplemental Figure 1a: SF-36. SF-36 mental component score among subjects randomized to SAMe or placebo, at baseline, Week.
C-SALT Study: grazoprevir + elbasvir in genotype 1 with Child-Pugh B cirrhosis Jacobson IM. EASL 2015, Abs. O008  Design Child-Pugh B GZR 100 mg + EBR.

C-SALT Study: grazoprevir + elbasvir in genotype 1 with Child-Pugh B cirrhosis Jacobson IM. EASL 2015, Abs. O008  Design Child-Pugh B GZR 100 mg + EBR.
Hepatitis web study Hepatitis web study Elbasvir-Grazoprevir in Treatment-Naïve HCV Genotype 1, 4 or 6 C-EDGE Treatment Naïve (TN) Phase 3 Treatment Naïve.

Hepatitis web study Hepatitis web study Elbasvir-Grazoprevir in Treatment-Naïve HCV Genotype 1, 4 or 6 C-EDGE Treatment Naïve (TN) Phase 3 Treatment Naïve.
Previous SVR With Interferon-Based Therapy for HCV Lowers Risk of Hepatotoxicity in HIV/HCV-Coinfected Individuals on Antiretroviral Therapy Slideset on:

Previous SVR With Interferon-Based Therapy for HCV Lowers Risk of Hepatotoxicity in HIV/HCV-Coinfected Individuals on Antiretroviral Therapy Slideset on:
Date of download: 7/10/2016 From: Four-Week Direct-Acting Antiviral Regimens in Noncirrhotic Patients With Hepatitis C Virus Genotype 1 Infection: An Open-Label,

Date of download: 7/10/2016 From: Four-Week Direct-Acting Antiviral Regimens in Noncirrhotic Patients With Hepatitis C Virus Genotype 1 Infection: An Open-Label,
ARV-trial.com RUBY-II Study: ombitasvir/paritaprevir/ritonavir + dasabuvir for HCV genotype 1a or 4 with severe renal impairment Design Open label W12.

ARV-trial.com RUBY-II Study: ombitasvir/paritaprevir/ritonavir + dasabuvir for HCV genotype 1a or 4 with severe renal impairment Design Open label W12.
eGFR (MDRD) > 50 mL/min

eGFR (MDRD) > 50 mL/min
Where Are We on the Path to Elimination of Chronic Hepatitis C?

Where Are We on the Path to Elimination of Chronic Hepatitis C?
Interim Analysis of a 3-Year Follow-up Study of NS5A and NS3 Resistance-Associated Variants After Treatment With Grazoprevir-Containing Regimens in Patients.

Interim Analysis of a 3-Year Follow-up Study of NS5A and NS3 Resistance-Associated Variants After Treatment With Grazoprevir-Containing Regimens in Patients.
EASL Recommendations on Treatment of Hepatitis C 2015 Treatment recommendations for HCV-monoinfected or HCV/HIV coinfected patients with chronic hepatitis.

EASL Recommendations on Treatment of Hepatitis C 2015 Treatment recommendations for HCV-monoinfected or HCV/HIV coinfected patients with chronic hepatitis.
Design Single arm Open label W12 ≥ 18 years, HCV genotype 1 to 6

Design Single arm Open label W12 ≥ 18 years, HCV genotype 1 to 6
C-ISLE study: EBR/GZR + SOF + RBV in genotype 3 and cirrhosis

C-ISLE study: EBR/GZR + SOF + RBV in genotype 3 and cirrhosis
Design Randomisation 2 : 1 Double-blind W12 ≥ 18 years, HCV genotype 3

Design Randomisation 2 : 1 Double-blind W12 ≥ 18 years, HCV genotype 3
No HBV or HIV co-infection

No HBV or HIV co-infection
Phase 3 Treatment-Naïve and Treatment-Experienced

Phase 3 Treatment-Naïve and Treatment-Experienced
AL study: AL ODV + SMV in naïve patients, phase II

AL study: AL ODV + SMV in naïve patients, phase II

Similar presentations

Ads by Google